Esperion Therapeutics, Inc. (ESPR) SEC Filing 8-K Material Event for the period ending Wednesday, May 23, 2018

Esperion Therapeutics, Inc.

CIK: 1434868 Ticker: ESPR

View differences made from one to another to evaluate Esperion Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Esperion Therapeutics, Inc..


Assess how Esperion Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Esperion Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: ESPR
CIK: 1434868
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-036428
Submitted to the SEC: Tue May 29 2018 4:32:24 PM EST
Accepted by the SEC: Tue May 29 2018
Period: Wednesday, May 23, 2018
Industry: Pharmaceutical Preparations
  1. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: